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Abstract
Outer- membrane vesicles (OMVs) produced by Helicobacter pylori deliver bacterial components to host cells, provide a mecha-
nism for stabilization of secreted components and may allow the bacteria to exert ‘long- range’ effects in the gastric niche, 
promoting persistence. In addition to their well- characterized host cell interactions, membrane vesicles improve stress survival 
in other bacterial species, and are constitutively produced by both pathogenic and non- pathogenic bacteria. We aimed to deter-
mine whether OMVs could improve H. pylori survival of a range of stressors. The effects of purified OMVs on the resistance of 
H. pylori to a range of environmental and antimicrobial stresses were determined using growth curves and survival assays. 
Addition of purified OMVs to H. pylori cultures provided dose- dependent protection against hydrogen peroxide- mediated killing. 
Supplementation with OMVs also partially protected H. pylori against the bactericidal effects of the antibiotics clarithromycin 
and levofloxacin, but not against amoxicillin nor metronidazole. Addition of purified OMVs allowed H. pylori to grow in the pres-
ence of inhibitory concentrations of the antimicrobial peptide LL-37. In the presence of 50 µg OMVs ml−1, significantly enhanced 
H. pylori growth was observed at higher LL-37 concentrations compared with lower LL-37 concentrations, suggesting that 
OMV–LL-37 interactions might facilitate release of growth- promoting nutrients. Taken together, these data indicate that pro-
duction of membrane vesicles could help H. pylori to survive exposure to antibiotics and host antimicrobial defences during 
infection.
InTRoduCTIon
Helicobacter pylori is a Gram- negative, microaerophilic 
bacterium that infects the human stomach during early 
childhood. If untreated, infection persists lifelong despite 
a robust immune response [1] and causes asymptomatic 
gastritis, which may progress to ulceration and the develop-
ment of gastric cancer [2, 3]. Treatment of H. pylori infection 
typically comprises a combination of amoxicillin with either 
clarithromycin or metronidazole administered with a proton 
pump inhibitor, but the failure rates of first- line triple thera-
pies, particularly those containing clarithromycin [4], have 
been climbing. A range of alternative triple and quadruple 
therapies are now recommended, depending on the local 
antibiotic- resistance rates [5]. Levels of antibiotic resist-
ance in H. pylori are escalating [4–7] and clarithromycin- 
resistant H. pylori was recently listed as one of the world’s 
highest priority antibiotic- resistant pathogens of concern 
by the World Health Organization [8]. There is a need for 
alternative therapies and better understanding of how 
H. pylori is able to persist lifelong in the harsh gastric 
environment.
Gram- negative bacteria, including H. pylori, constitutively 
release outer- membrane vesicles (OMVs) during normal 
growth [9, 10]. OMVs are small (20–300 nm), spherical 
vesicles predominantly containing outer membrane and 
periplasmic components from the bacterial cell [11]. H. pylori 
OMVs contain virulence factors including the toxin VacA 
[10, 12, 13] and are readily taken up by host cells [14, 15].
Roles for bacterial OMVs in host–pathogen interactions 
have been widely reported (reviewed by Schwechheimer 
and Kuehn, and MacDonald and Kuehn [11, 16]), but non- 
pathogenic bacteria also produce OMVs. Production of 
OMVs is upregulated in response to, and associated with 
survival of, stress in Pseudomonas aeruginosa [17] and 
Escherichia coli [18, 19], and OMVs contribute to bacterial 
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survival of antibiotic treatment in E. coli [20, 21] and Pseu-
domonas syringae [22].
Protective effects of OMVs against oxidative stress in H. pylori 
were recently reported using strains P12 and 18943 [23]. If 
the production of OMV can help H. pylori to survive stressors 
such as the host immune response and antibiotic treatment, 
then it might be possible to increase the susceptibility of 
H. pylori to immunity and therapy, and/or reduce the viru-
lence of the infection, by designing new therapies that inter-
fere with vesiculation.
In this study, we aimed to determine whether OMVs could 
protect H. pylori against a range of stressors. Hydrogen 
peroxide and the cathelicidin derivative LL-37, a cationic 
antimicrobial peptide involved in the human gastric mucosal 
defence against H. pylori [24], were used to simulate immune- 
mediated stressors, and the protective effects of OMVs against 
antibiotics commonly used to treat H. pylori infections were 
also assessed.
METHodS
Culture of H. pylori
H. pylori strain 60190 was provided by Professor John 
Atherton and his team at the University of Nottingham, UK. 
The bacteria were routinely cultured on blood agar base no. 
2 (Oxoid) supplemented with 7.5 % defibrinated horse blood 
(TCS Biosciences) under microaerobic conditions (85 % N2, 
10 % CO2, 5 % O2) at 37 °C.
Purification of oMVs
For most of the reported assays, OMVs were isolated from 
late exponential or early stationary phase broth cultures of 
H. pylori in serum- free media [brain heart infusion (BHI) 
broth supplemented with 0.2 % β-cyclodextrin]. For some 
of the antimicrobial survival assays, to improve the yield of 
OMVs (since H. pylori growth in serum- free liquid media is 
very slow), OMVs were isolated directly from bacteria that 
were grown on agar plates then re- suspended in media. Bacte-
rial cells were removed by centrifugation at 4000 g for 10 min 
and sequential filtration of the culture supernatant through 
0.45 and 0.20 µm syringe filters. OMVs were purified from 
the culture supernatants by centrifugation at 100 000 g for 
2 h at 4 °C, with a preceding 40 % ammonium sulfate precipi-
tation step to concentrate the secreted proteins and OMVs 
from larger culture volumes, as previously described [25]. 
The OMV pellets were washed using particle- free Dulbecco’s 
PBS (Sigma Aldrich) and finally re- suspended in 200–500 µl 
PBS. OMVs were quantified using a Pierce BCA protein assay 
(Fisher Scientific) and stored promptly at −20 °C until use.
Hydrogen peroxide survival assay
H. pylori were grown for 24 h on blood agar and then 
suspended to OD600 0.1 in Iso- Sensitest broth (Oxoid) + 5 % 
(v/v) FCS (Sigma Aldrich). Bacteria were mixed with a final 
concentration of 0–50 µg OMVs ml−1 or 0.1 % (w/v) bovine 
catalase in triplicate in sterile 96- well plates and then H2O2 
was added to all wells to a final concentration of 1 mM. After 
2.5 h incubation at 37 °C, samples were taken from each well 
and diluted into 1 % (w/v) bovine catalase to inactivate any 
residual H2O2 before Miles and Misra determination of the 
number of c.f.u. ml−1.
Growth inhibition assay
H. pylori were grown for 24 h on blood agar and then 
suspended in BHI broth + 0.2 % β-cyclodextrin to OD600 0.1, 
supplemented with either 50 µg OMVs ml−1 in PBS or an equal 
volume of PBS without OMVs. Bacteria with and without 
OMVs were then incubated with 0.25–1.0 µg amoxicillin 
ml−1 (Sigma Aldrich) or 1.25–5.0 µg LL-37 ml−1 (InvivoGen) 
in 96- well plates under microaerobic conditions, and bacte-
rial growth was monitored by measuring the OD600 at 24 h 
intervals for 1 week.
Antimicrobial survival assays
Bacteria were adjusted to OD600 0.1 in BHI broth + 0.2 % 
β-cyclodextrin and treated with the antimicrobial peptide 
LL-37 (InvivoGen) or the antibiotics amoxicillin, clarithro-
mycin, metronidazole or levofloxacin (all from Sigma Aldrich) 
at the concentrations indicated in the figures, in the presence 
of 0–25 µg purified OMVs ml−1. Survival assays were set up 
in triplicate wells in sterile 96- well plates, in a total volume of 
100 µl per well. After incubation in microaerobic conditions at 
37 °C for 3 h, the surviving bacteria were quantified by serial 
dilution and plating out. Data were expressed as c.f.u. ml−1 and 
as percentage survival compared to the bacterial c.f.u. ml−1 in 
untreated control wells.
Heat treatment of oMVs
Heat- treated OMVs were prepared by heating purified OMVs 
at 80 °C for 10 min, cooling to room temperature and then 
briefly centrifuging the heated OMV suspension to bring all 
liquid to the bottom of the tube.
Statistical analysis
GraphPad Prism 8.1.2 was used for statistical analysis and 
figure generation. The tests used are indicated in each figure.
RESuLTS
Membrane vesicles can protect H. pylori against 
hydrogen peroxide-mediated killing in a dose-
dependent manner
H. pylori OMVs are enriched with catalase [23], which is 
thought to contribute to bacterial survival of oxidative stress 
in the human stomach. We treated H. pylori with 1 mM H2O2 
and measured bacterial survival using colony counts after 
2.5 h. H2O2 treatment caused greater than 8- log reduction in 
c.f.u. ml−1 compared to a control that included 0.1 % bovine 
catalase to inactivate the H2O2 (Fig. 1).
To assess potential protective effects of OMVs against 
oxidative stress, OMVs were purified from stationary phase 
serum- free H. pylori culture supernatant by filtration and 
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ultracentrifugation, suspended in PBS and confirmed free of 
viable bacteria by incubating samples on blood agar plates 
under microaerobic conditions for several days. Addition of 
OMVs protected H. pylori against H2O2- mediated killing in 
a dose- dependent manner (Fig. 1; P<0.05). Concentrations 
of OMVs at or above 12.5 µg ml−1 provided similar levels of 
protection against H2O2 to 0.1 % bovine catalase.
Supplementation with membrane vesicles allows H. 
pylori to grow in the presence of the antimicrobial 
peptide LL-37
LL-37 is a cationic antimicrobial peptide involved in mucosal 
immune defence, and OMVs have previously been shown to 
protect Vibrio cholerae against this peptide [26]. LL-37 inhib-
ited the growth of H. pylori when included in the growth media 
at concentrations between 1.25 and 5 µg ml−1, but growth in 
the presence of all concentrations of LL-37 was significantly 
enhanced (P<0.05) when the cultures were supplemented 
with 50 µg OMVs ml−1 (Fig.  2a). OMV- mediated growth 
promotion was greatest at the highest LL-37 concentration. 
OMVs were not able to enhance the growth of H. pylori in the 
presence of amoxicillin (Fig. 2b).
Membrane vesicles can promote H. pylori survival 
of antibiotic treatment
H. pylori incubated for 3 h in the presence of clarithromycin, 
metronidazole or levofloxacin had significantly reduced 
survival compared to untreated control bacteria (P<0.001 
for each antibiotic, two- way ANOVA with Dunnett’s multiple 
comparisons tests). Addition of 25 µg purified OMVs ml−1 
improved bacterial survival in the presence of clarithromycin 
and levofloxacin, but not metronidazole (Fig. 3).
Since the protective effect of OMVs was most dramatic 
for clarithromycin treatment, we studied it in more detail. 
We reduced the clarithromycin concentration from 10 to 
5 µg ml−1 (sufficient to cause a several log reduction in 
bacterial viability) and tested a range of OMV concen-
trations for potential protective effects. OMVs protected 
H. pylori against clarithromycin- mediated killing in a 
dose- dependent manner (Fig. 4) and the protective effect 
of OMVs was not ablated by pre- heating them to 80 °C for 
10 min to inactivate any OMV- associated enzymes (Fig. 5).
dISCuSSIon
Constitutive production of OMVs during growth is now 
understood to be a well- characterized and highly conserved 
feature of all Gram- negative bacteria studied to date. Contin-
uous packaging and export of cellular components is ener-
getically expensive, so OMV secretion must perform some 
important beneficial functions. Given that OMV production 
is upregulated in response to stress in some species, the 
contribution of vesiculation to bacterial survival of environ-
mental stress has been proposed as one such universal benefit 
of OMV production [17–19].
H. pylori is able to persist in the harsh environment of the 
human stomach for decades, despite a vigorous immune 
response by the host [1]. Consistent with the recent report 
by Lekmeechai et al. [23], but using a different H. pylori strain, 
we found that addition of purified OMVs could enhance 
Fig. 1. Viability of H. pylori in the presence of 1 mM H
2
O
2
 is restored by supplementation with OMVs. Bacteria were incubated at 37 °C in 
Iso- Sensitest broth, 5 % (v/v) FCS with 1 mM H
2
O
2
 and viability determined after 2.5 h by the Miles and Misra method. Triplicate means ± 
sd are shown. Bacterial viability was reduced by H
2
O
2
 treatment compared to the control in which H
2
O
2
 was inactivated using 0.1 % (w/v) 
bovine catalase (bKatA). Bacterial viability was restored to control levels by the addition of purified OMVs, in a dose- dependent manner. 
Asterisks indicate statistically significant differences compared to H
2
O
2
- treated bacteria without the addition of bKatA or OMVs (non- 
parametric Kruskal–Wallis test with multiple comparisons by Dunn’s test; multiplicity corrected P values reported; *P<0.05).
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H. pylori survival of hydrogen peroxide treatment in a dose- 
dependent manner. Using a katA mutant, Lekmeechai et al. 
[23] showed that the protective effects of H. pylori OMV 
against hydrogen peroxide were mediated by the catalase 
enzyme.
We also found that OMVs were protective against the anti-
microbial peptide LL-37 that is produced by human gastric 
epithelial cells in response to infection and is bactericidal 
to H. pylori [24]. This protective effect is presumably due 
to sequestration of LL-37 by OMVs, as previously shown 
for other membrane active antimicrobial peptides in other 
bacterial species, for example E. coli and P. syringae OMVs 
versus colistin and melittin [20, 22], and V. cholerae versus 
polymyxin B and LL-37 [26].
Addition of OMVs alleviated the LL-37- mediated inhibition 
of H. pylori growth at all LL-37 doses tested but, curiously, 
growth of OMV- supplemented H. pylori was greatest at the 
highest concentrations of LL-37. It is unclear how OMV 
addition might have caused this observed trend, but it is 
possible that the lysing of OMVs by LL-37 resulted in the 
dispersal of packaged nutrients for the surviving H. pylori 
cells. Alternatively, proteolytic enzymes in the OMVs might 
have digested LL-37, effectively supplementing the culture 
media with amino acids to promote bacterial growth. Further 
Fig. 2. OMVs can protect H. pylori against the antimicrobial peptide LL-37, but not against amoxicillin. Bacteria were grown in different 
concentrations of LL-37 (a) or amoxicillin (b) as indicated by the keys, with (dashed lines) or without (solid lines) supplementation with 
50 µg purified OMVs ml−1 . Growth of H. pylori 60190 in BHI + 0.2 % β-cyclodextrin was inhibited by 1.25–5 µg LL-37 ml−1 . When the bacteria 
were supplemented with 50 µg purified OMVs ml−1, growth was significantly enhanced (endpoint P<0.05, two- way ANOVA with Tukey post 
hoc tests) (a). OMVs did not enhance the growth of H. pylori in the presence of amoxicillin (b).
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Fig. 3. Protective effects of OMVs against clarithromycin treatment. H. pylori were incubated for 3 h in the presence of 10 µg clarithromycin 
ml−1, 100 µg metronidazole ml−1 or 10 µg levofloxacin ml−1. These concentrations of drug were sufficient to significantly reduce bacterial 
survival (***P<0.001, two- way ANOVA with Dunnett’s multiple comparisons tests versus the untreated control group). The limit of 
detection, 33 c.f.u. ml−1, is indicated by dashed lines. Supplementation with 25 µg purified OMVs ml−1 improved bacterial survival of 
clarithromycin and levofloxacin treatment, but not metronidazole. After OMV supplementation, bacterial survival was not significantly 
different to the untreated control group. Data shown are mean c.f.u. ml−1 ± sd (a) and percentage survival compared to the untreated 
control group (b) for three independent replicates.
Fig. 4. OMV- mediated protection of H. pylori against clarithromycin treatment is dose- dependent. Bacteria were suspended in BHI broth 
and exposed to 5 µg clarithromycin ml−1 (black bars) with and without the addition of the indicated concentrations of purified OMVs. After 
3 h incubation at 37 °C under microaerobic conditions, the surviving bacteria were quantified by serial dilution and plating. Data are 
expressed as c.f.u. ml−1 (a) and percentage survival compared to untreated bacteria (b). Untreated bacteria (white bars) were incubated in 
BHI broth without clarithromycin and OMVs. Mean values ± sd from three independent replicates are shown. Addition of 25 µg OMVs ml−1 
significantly protected H. pylori against clarithromycin treatment (****P<0.0001, one- way ANOVA with Dunnett’s multiple comparison test 
versus the clarithromycin- treated control without addition of OMVs).
6Murray et al., Microbiology 2020
mechanistic studies will be needed to characterize the interac-
tions between bacterial OMVs and LL-37.
Treatment of H. pylori and other bacterial infections is 
becoming increasingly difficult due to the development of 
antibiotic resistance. Improved understanding of bacterial 
mechanisms of antibiotic resistance and tolerance could 
help inform the design of new treatments, so we investigated 
the potential for OMVs to protect H. pylori against exposure 
to antibiotics. Although OMV- mediated protection against 
β-lactam antibiotics has been reported for other species, 
for example Staphylococcus aureus [27] and Acinetobacter 
baumannii [28], this protection was dependent on the 
activity of β-lactamase enzyme exported with or inside the 
vesicles. Since the development of amoxicillin resistance in 
H. pylori does not depend on β-lactamase production [29], it 
is unsurprising that H. pylori- derived OMVs were not directly 
protective against amoxicillin.
We observed a modest protective effect of OMVs against levo-
floxacin treatment, but not against metronidazole. In contrast, 
OMV- mediated protection of H. pylori against exposure to 
clarithromycin was dramatic and dose- dependent. OMVs 
were still able to protect H. pylori against clarithromycin treat-
ment after heat treatment at 80 °C, indicating that a heat- labile 
enzymatic activity was not likely to be responsible for this 
protective effect, although more comprehensive analysis will 
be required to definitely rule out an enzyme- based mecha-
nism. Clarithromycin is a macrolide antibiotic that inhibits 
protein synthesis by targeting the 23S rRNA region in the 
50S ribosomal subunit. Mutations A2143G and A2142G/C 
in the target region of the 23S rRNA are the most common 
causes of clarithromycin resistance in H. pylori in Europe 
(reviewed by Xuan et al. [30]). The mechanism driving OMV- 
mediated protection of H. pylori against clarithromycin in 
our study has not yet been elucidated. Simple sequestration 
is one possible explanation – clarithromycin is a hydro-
phobic antibiotic and enters bacterial cells via lipid- mediated 
passive diffusion [31, 32], and macrolide antibiotics can bind 
directly to lipid membranes [33], so OMVs may have acted 
as a decoy taking up clarithromycin that would otherwise 
have diffused into bacterial cells. However, levofloxacin has 
Fig. 5. Heat treatment does not prevent OMV- mediated protection of H. pylori against clarithromycin. Bacteria were suspended in BHI 
broth and exposed to 5 µg clarithromycin ml−1 (black bars) with and without 25 µg purified OMVs ml−1. The OMV label indicates that normal 
purified OMVs were added. OMV + heat indicates that the OMVs were pre- treated with heat (80 °C for 10 min) before use in the assay. 
After 3 h incubation at 37 °C under microaerobic conditions, the surviving bacteria were quantified by serial dilution and plating. Data are 
expressed as c.f.u. ml−1 (a) and percentage survival compared to untreated bacteria (b). Untreated bacteria (white bar) were incubated 
in BHI broth without clarithromycin and OMVs. Mean values ± sd from three independent replicates are shown. The limit of detection, 
33 c.f.u. ml−1, is indicated by a dashed line. Addition of 25 µg OMVs ml−1 significantly protected H. pylori against clarithromycin treatment 
(**P<0.01, one- way ANOVA with Tukey’s multiple comparison tests) and there was no significant difference in the protective effects of 
heat- treated versus non- heat- treated OMVs. ns, No significant difference.
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intermediate lipophilicity and metronidazole is also lipo-
philic, so a comprehensive study of drug–OMV interactions 
is needed to assess the potential for vesicles to adsorb each 
drug. The presence or absence of potential molecular targets 
for clarithromycin in OMVs, and their binding affinities 
for the drug, should also be determined. Recent genomic 
analysis of clarithromycin- sensitive and -resistant H. pylori 
strains has identified additional mutations associated with 
clarithromycin susceptibility, including membrane proteins 
[34], and the expression of some outer- membrane proteins is 
upregulated in clarithromycin- resistant strains [35].
Further work is needed to elucidate the mechanisms by 
which H. pylori OMVs can protect the bacteria against LL-37 
and clarithromycin, and to assess whether OMV- mediated 
survival and growth promotion are biologically relevant in 
vivo. It is not yet clear what concentrations of OMVs are 
present in vivo during bacterial infections, but it is possible 
that local OMV concentrations could become relatively high 
in the context of biofilm and/or thick mucus layers. Further 
study of in vivo OMV production is needed.
In some other bacterial species, exposure to stressors has 
been shown to cause upregulation of vesiculation [19] and/
or modulation of OMV contents [26], and it would be useful 
to determine which antimicrobial treatments might modulate 
the rate of vesiculation by H. pylori. Comprehensive mapping 
of the OMV biogenesis pathways of H. pylori is also needed, 
to identify candidate targets for novel anti- vesiculation drugs. 
If such drugs could be developed, they might reduce bacterial 
stress survival and virulence by disabling OMV production, 
in turn potentiating the antibacterial activities of conventional 
antibiotics and the host immune response.
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